Ask AI
ProCE Banner Activity

Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma

Podcast Episodes

Listen to this podcast to hear Sagar Lonial, MD, FACP, FASCO, and Mohamad Mohty, MD, PhD, discuss recent advances, future directions, and the integration of novel protein degradation modulator-based therapy into myeloma care, including what clinicians may expect when incorporating these therapies into practice.

Released: July 01, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the mechanistic and clinical rationales for combining novel agents with protease inhibitors, anti-BCMA T-cell engagers, and other standard antimyeloma therapies

  • Assess how emerging data for novel agent-based regimens could impact near-future treatment options for patients with newly diagnosed through heavily pretreated multiple myeloma

  • Identify patients with multiple myeloma who are likely to benefit from novel agent-based therapies under clinical trial investigation